Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)

Abstract. Riociguat, a soluble guanylate cyclase stimulator developed for the treatment of pulmonary hypertension, is metabolized in part by the liver. Expression of one of the metabolizing enzymes, CYP1A1, is induced by aromatic hydrocarbons in tobacco smoke. Two nonrandomized, nonblinded studies w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pulm Circ
Hlavní autoři: Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mück, Wolfgang
Médium: Artigo
Jazyk:Inglês
Vydáno: University of Chicago Press 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860536/
https://ncbi.nlm.nih.gov/pubmed/27162628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/685015
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky